iLIVER最新文献

{"title":"Precise cell therapy for liver fibrosis: Endothelial cell and macrophage therapy","authors":"Liping Deng ,&nbsp;Bingjie Wu ,&nbsp;Kaini Liang,&nbsp;Hongen Liao,&nbsp;Yanan Du","doi":"10.1016/j.iliver.2022.11.002","DOIUrl":"10.1016/j.iliver.2022.11.002","url":null,"abstract":"<div><p>Liver fibrosis is typically caused by chronic viral hepatitis and, more recently, fatty liver disease associated with obesity. There are currently no approved drugs for liver cirrhosis, and liver transplantation is limited by donor scarcity, thus driving the investigation of novel therapeutic strategies. The development of liver fibrosis presents with stage- and zone-dependent characteristics that manifest as distinct dynamic changes during vascularization and extracellular matrix (ECM) deposition. However, current cellular therapies do not consider the spatiotemporal variations of liver fibrosis without identifying the precise location and stage to administer the intervention to achieve optimal therapeutic effects. Herein, we focus on endothelial cell (EC) and macrophage therapy for liver fibrosis because of their important roles in regulating the spatiotemporal changes of vascularization and ECM deposition during liver fibrosis progression. Overall, this review summarizes the stage-dependent EC and macrophage therapy for liver fibrosis, elucidates their respective mechanisms, and exemplifies potential strategies to realize precise cell therapy by targeting specific liver zones.</p></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"1 4","pages":"Pages 265-274"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947822000792/pdfft?md5=abba7c1fd4c27429dc4e5db717b3cd51&pid=1-s2.0-S2772947822000792-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88165856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transarterial chemoembolization in combination with programmed death-1/programmed cell death-ligand 1 immunotherapy for hepatocellular carcinoma: A mini review","authors":"Jingxin Yan ,&nbsp;Manjun Deng ,&nbsp;Shunyu Kong ,&nbsp;Ting Li ,&nbsp;Zhenwu Lei ,&nbsp;Lushun Zhang ,&nbsp;Yutong Zhuang ,&nbsp;Xin He ,&nbsp;Huanwei Wang ,&nbsp;Haining Fan ,&nbsp;Yingxing Guo","doi":"10.1016/j.iliver.2022.10.001","DOIUrl":"10.1016/j.iliver.2022.10.001","url":null,"abstract":"<div><p>Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide. With the development of systemic therapies, several studies are currently underway, especially those related to the use of programmed death-1/programmed cell death-ligand 1 (PD-1/PD-L1) immunotherapy. Moreover, studies on transarterial chemoembolization (TACE) and PD-1/PD-L1 immunotherapy have demonstrated some interesting outcomes. This article reviewed the current clinical evidence on the combination of TACE and PD-1/PD-L1 immunotherapy. Overall, our review summarized that a favorable survival time could be achieved using this combination in most patients. However, complications such as hyperprogression should be taken seriously, and the underlying mechanisms need to be explored.</p></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"1 4","pages":"Pages 225-234"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947822000688/pdfft?md5=12c39e93d255971c017128516bd0799d&pid=1-s2.0-S2772947822000688-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90971385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Position statement of Hepatology Society, Dhaka, Bangladesh onManagement of acute variceal bleeding in a resource-limited setting","authors":"T. Ahmad, Shahinul Alam, S. Islam, G. Azam, M. Alam, SKMNazmul Hasan, Golam Mustafa, Motahar Hossain, Md. Akmat Ali, Mobin Khan","doi":"10.1016/j.iliver.2022.11.004","DOIUrl":"https://doi.org/10.1016/j.iliver.2022.11.004","url":null,"abstract":"","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"99 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76665667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advanced therapies for congenital biliary tract malformation: From bench to bedside","authors":"Yixuan Shao ,&nbsp;Xinyu Yang ,&nbsp;Hao Chen ,&nbsp;Di Lu ,&nbsp;Yonggang Huang ,&nbsp;Xiao Xu","doi":"10.1016/j.iliver.2022.08.003","DOIUrl":"10.1016/j.iliver.2022.08.003","url":null,"abstract":"<div><p>Congenital biliary tract malformations are a series of rare but extremely serious diseases that mainly include biliary atresia and biliary hypoplasia (referred to as Alagille syndrome). The rapid progression of biliary atresia and Alagille syndrome results in jaundice, cholestatic liver disease, cirrhosis, and even liver failure. In most cases, supportive or clinically specific therapies cannot achieve satisfactory outcomes. Therefore, liver transplantation (especially living donor liver transplantation) may be required. As many studies have elucidated the role of genetic factors and the molecular mechanism of congenital biliary tract malformations, experimental therapies such as organoid transplantation, cell therapy, and immunotherapy have been proved to be feasible. These advanced methods have shown outstanding advantages, particularly in patients with end-stage biliary tract malformations, surgery failure, and other problems that cannot be solved by conventional therapies. This review article discusses the potential pathogenesis of and promising therapeutic strategies for biliary tract malformations.</p></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"1 3","pages":"Pages 159-168"},"PeriodicalIF":0.0,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947822000421/pdfft?md5=0f9cea160b439c80620dd8cc6d2c2d35&pid=1-s2.0-S2772947822000421-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76159180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The APR triangle: A practical zone in the Glissonean approach to laparoscopic anatomical right hepatectomy","authors":"Jie Chen ,&nbsp;Ziyu Zhang ,&nbsp;Rui Zhou ,&nbsp;Anzhi Wang ,&nbsp;Jun Cao ,&nbsp;Yajin Chen","doi":"10.1016/j.iliver.2022.08.004","DOIUrl":"10.1016/j.iliver.2022.08.004","url":null,"abstract":"<div><h3>Background</h3><p>An understanding of vascular anatomy is crucial for the safe performance of laparoscopic anatomical liver excision. We discovered a triangular zone during the laparoscopic right liver surgery and termed this zone the APR triangle. The purpose of this study was to determine the probability of the existence of the APR triangle and elucidate its various forms.</p></div><div><h3>Methods</h3><p>Analyzed three-dimensional image reconstructions of 66 individuals who underwent liver surgery and calculated the statistics for various types of APR triangles under various grouping settings.</p></div><div><h3>Results</h3><p>The APR triangle was present in the majority of cases, with right hepatic vein trunk type in 68% and right hepatic vein branch type in 21%, respectively. The angle between the right anterior and right posterior hepatic pedicles (AP&amp;PP) was at most between 45 and 90° (74%). There was a 35% chance that at least one of the AP&amp;PP was longer than 2 cm, and a 39% chance that both were. The right posterior pedicle first branch would appear at the bifurcation of AP&amp;PP in 13% only.</p></div><div><h3>Conclusions</h3><p>The APR triangle is objectively present and may represent a practical zone for performing laparoscopic right hepatic anatomical resection more simply and safely.</p></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"1 3","pages":"Pages 176-180"},"PeriodicalIF":0.0,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947822000433/pdfft?md5=d5734e639a515f21816aba13a662a170&pid=1-s2.0-S2772947822000433-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77576635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tenofovir disoproxil fumarate therapy in patients with chronic hepatitis B and advanced fibrosis or compensated cirrhosis","authors":"Huiying Rao ,&nbsp;Jia Shang ,&nbsp;Qing Xie ,&nbsp;Jianqi Lian ,&nbsp;Pujun Gao ,&nbsp;Junping Shi ,&nbsp;Xinyue Chen ,&nbsp;Jiefei Wang ,&nbsp;Min Xu ,&nbsp;Liaoyun Zhang ,&nbsp;Yingren Zhao ,&nbsp;Qing Mao ,&nbsp;Maorong Wang ,&nbsp;Wei Zhao ,&nbsp;Zong Zhang ,&nbsp;Jidong Jia ,&nbsp;Hong Tang ,&nbsp;Jiming Zhang ,&nbsp;Xin Zheng ,&nbsp;Chang Liu ,&nbsp;Lai Wei","doi":"10.1016/j.iliver.2022.08.006","DOIUrl":"10.1016/j.iliver.2022.08.006","url":null,"abstract":"<div><h3>Background and aims</h3><p>Tenofovir disoproxil fumarate (TDF) is the first-line therapy for chronic hepatitis B. This interim analysis presents the efficacy and safety data for TDF at Week 144 in patients with chronic hepatitis B and advanced fibrosis or compensated cirrhosis from China.</p></div><div><h3>Methods</h3><p>Patients were assessed for incidence of newly diagnosed hepatocellular carcinoma (HCC) and disease progression, liver stiffness measurement (LSM), virological suppression (serum hepatitis B virus DNA &lt;20 IU/mL), alanine aminotransferase normalization, hepatitis B e antigen (HBeAg) loss and seroconversion, histological liver fibrosis score, and safety at Week 144.</p></div><div><h3>Results</h3><p>Overall, 197 patients were enrolled. At Week 144, the incidence of newly diagnosed HCC was observed in 2.1% patients, and the incidence of disease progression was observed in 3.6% patients. The mean (standard deviation) change in LSM from baseline was −5.1 (5.85) kPa. Serum hepatitis B virus DNA &lt;20 IU/mL was observed in 94.1% patients, alanine aminotransferase normalization in 33.5% patients, HBeAg loss in 35.6% patients, and HBeAg seroconversion in 14.4% patients. Among patients with stage F3 or F4 fibrosis at baseline by LSM, 38.3% patients regressed to stage F0/1, and 22.0% of patients regressed to stage F2 at Week 144. Overall, 67.7% patients experienced ≥1 adverse events, 13.8% patients experienced TDF-related adverse events, and 16.4% patients experienced serious (none were TDF-related).</p></div><div><h3>Conclusions</h3><p>At Week 144 of TDF treatment, low incidence of HCC and disease progression were reported. Virological suppression was observed in 94.1% patients, which was associated with fibrosis regression. No new safety events were identified.</p></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"1 3","pages":"Pages 145-153"},"PeriodicalIF":0.0,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947822000652/pdfft?md5=894253d87b76d64c2ddaf43722986e02&pid=1-s2.0-S2772947822000652-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74546618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A linear relationship between De Ritis ratio and mortality in hospitalized patients with COVID-19: A secondary analysis based on a large retrospective cohort study","authors":"Yanling Fu,&nbsp;Shouwen Du,&nbsp;Xiaodi Liu,&nbsp;Lin Cao,&nbsp;Guilin Yang,&nbsp;Hongtao Chen","doi":"10.1016/j.iliver.2022.08.002","DOIUrl":"10.1016/j.iliver.2022.08.002","url":null,"abstract":"<div><h3>Background and aims</h3><p>Although some studies have identified a possible link between the De Ritis ratio and the mortality of patients with COVID-19), the predictive value and the optimal cut-value remain unclear. This study aimed to explore the correlation between the De Ritis ratio and mortality in hospitalized COVID-19 .</p></div><div><h3>Methods</h3><p>The data for this cohort study came from a retrospective cohort study that was carried out in a medical system in New York City. The primary outcome was the in-hospital mortality of included patients. The researchers ran multivariate Cox regression analyses, curve fitting, and subgroup analysis to support our findings. Overall survival in different De Ritis ratio groups was plotted as Kaplan–Meier survival curves.</p></div><div><h3>Results</h3><p>The study enrolled 4371 participants with COVID-19 from March 1, 2020 to April 16, 2020. The overall mortality was 24.8% (1082/4371). The curve fitting analyses indicated that the De Ritis ratio has a positive linear connection with mortality in patients with COVID-19. After adjusting for all covariates, participants with a De Ritis ratio ≥2 exhibited 1.29 times the risk of in-hospital mortality compared with those with a De Ritis ratio &lt;1 (hazard ratio 1.29, 95% confidence interval 1.02–1.62, <em>p</em> = 0.031). The <em>p</em> for trend was &lt;0.05 for all models. Patients in the group with a De Ritis ratio ≥2 experienced the shortest survival time in the Kaplan–Meier survival analysis.</p></div><div><h3>Conclusions</h3><p>A higher baseline De Ritis ratio is correlated with a corresponding higher mortality among hospitalized people with COVID-19.</p></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"1 3","pages":"Pages 169-175"},"PeriodicalIF":0.0,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S277294782200041X/pdfft?md5=5e4db98f5f62a23d19fa0a36974d1ea8&pid=1-s2.0-S277294782200041X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87792020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A retrospective study of PD-L1 immunohistochemistry for hepatocellular carcinoma","authors":"Min Du ,&nbsp;Yumeng Cai ,&nbsp;Yanrui Pang ,&nbsp;Yuan Ji","doi":"10.1016/j.iliver.2022.08.005","DOIUrl":"10.1016/j.iliver.2022.08.005","url":null,"abstract":"<div><h3>Background</h3><p>Programmed cell death ligand 1 (PD-L1) expression plays an important role in selecting patients with hepatocellular carcinoma who will benefit from anti-programmed cell death 1 (PD-1)/PD-L1 monotherapy and directing those with lower levels to alternative treatments.</p></div><div><h3>Methods</h3><p>In total, 156 hepatocellular carcinoma tumors were stained with three PD-L1 immunohistochemistry assays (SP142, 28-8, and E1L3N). Two junior pathologists and one senior pathologist evaluated the pathological slides and recorded the percentages of tumor and immune cells stained at any intensity.</p></div><div><h3>Results</h3><p>Analytical comparisons demonstrated that the anti-PD-L1 assay SP142 is a significantly stronger reagent that stains a higher percent of both tumor and immune cells, while 28-8 and E1L3N behave similarly to each other. The correlation coefficients of the three assays ranged from 0.77 to 0.92 for tumor cells and from 0.66 to 0.75 for immune cells. Next, 1% and 5% tumor cell staining cutoffs were designated using various combinations of assays and cutoffs. Across all three reagents, 14 samples showed concordance above the 5% threshold, eight showed concordance within the range of 1% to 5% interval, and 93 showed concordance below the 1% threshold. The remaining 41 samples showed a combination of discordant results across all three reagents. High PD-L1 expression in tumor and immune cells tended to not be recurrent.</p></div><div><h3>Conclusions</h3><p>The anti-PD-L1 assays 28-8 and E1L3N were closely aligned with regard to staining tumor and immune cells, whereas SP142 showed higher percentages of staining for both cell types. All three assays indicated greater variability in immune cell staining than in tumor cells.</p></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"1 3","pages":"Pages 187-193"},"PeriodicalIF":0.0,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947822000445/pdfft?md5=05fdf2a805b563dcba79064683c97efa&pid=1-s2.0-S2772947822000445-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79631103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multi-feature weight factor extraction and survival risk assessment of hepatocellular carcinoma based on a clinical missing dataset-independent support vector machine","authors":"Fumin Wang ,&nbsp;Nan Zhang ,&nbsp;Xiaoning Wu ,&nbsp;Wei Zhang ,&nbsp;Qiang Lu ,&nbsp;Rongqian Wu ,&nbsp;Xu-Feng Zhang ,&nbsp;Hui Guo ,&nbsp;Yi Lv","doi":"10.1016/j.iliver.2022.07.003","DOIUrl":"10.1016/j.iliver.2022.07.003","url":null,"abstract":"<div><h3>Background</h3><p>In clinical datasets, the characteristics of an individual patient vary so much that data loss becomes a normal event, which may be a unignorable dilemma in clinical data analysis. Therefore, the construction of a machine learning model aimed at missing clinical datasets (MCD) is of great clinical importance.</p></div><div><h3>Methods</h3><p>All included patients were divided into two groups according to outcome within a period of up to 36 months or less. The following characteristics (variables) were collected: age, sex, Child–Pugh status, hepatitis status, cirrhosis status, treatment, tumor size, portal vein tumor thrombus, and alpha fetoprotein (μg/mL), and a missing dataset-independent support vector machine (MDI-SVM) independent of missing data was built for the analysis.</p></div><div><h3>Results</h3><p>A MCD-independent SVM was developed based on clinical data from 1334 patients with hepatocellular carcinoma (HCC) at a single center, which had an accuracy of 84.43% in the survival analysis in the presence of 5% missing data. Based on the different combinations of features, our model calculated five features (tumor size, age, treatment, hepatitis status, and alpha fetoprotein) that had the greatest impact on survival in patients with HCC and extracted their weighting factors.</p></div><div><h3>Conclusions</h3><p>A MCD-independent SVM was developed to achieve prognosis prediction for patients with HCC in the absence of first-visit data.</p></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"1 3","pages":"Pages 154-158"},"PeriodicalIF":0.0,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947822000408/pdfft?md5=8b358f4a4124596b0f47c2d8785d3028&pid=1-s2.0-S2772947822000408-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73415729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MAFLD was more easily diagnosed than NAFLD in liver transplant recipients with abnormal liver function","authors":"Dali Zhang ,&nbsp;Hongbo Wang ,&nbsp;Xi He,&nbsp;Danni Feng,&nbsp;Yanling Sun,&nbsp;Zhenwen Liu,&nbsp;Yinjie Gao,&nbsp;Hongling Liu","doi":"10.1016/j.iliver.2022.09.001","DOIUrl":"10.1016/j.iliver.2022.09.001","url":null,"abstract":"<div><h3>Background and aims</h3><p>Nonalcoholic fatty liver disease (NAFLD) is hepatic steatosis that is require the exclusion of certain etiologies, including drug usage or alcoholic consumption. Conversely, metabolic dysfunction-associated fatty liver disease (MAFLD) needs not to. In this study, we aimed to examine whether MAFLD is more easily diagnosed than NAFLD in liver transplant (LT) recipients with abnormal liver function.</p></div><div><h3>Methods</h3><p>In this cross-sectional study, LT recipients with abnormal liver function were investigated for the prevalence of MAFLD and NAFLD.</p></div><div><h3>Results</h3><p>We recruited 57 LT recipients with abnormal liver function at a referral hospital. Among these patients, the prevalence of MAFLD and NAFLD was 37.8% and 11.1%, respectively. 17 patients showed hepatic steatosis, with an average NAFLD activity score of 3.5 and a fibrosis score of 1.0. Compared with non-MAFLD patients, MAFLD patients had a significant difference in fasting blood glucose levels (<em>p</em> = 0.009). Among 17 MAFLD patients, 12 were overweight and four were diagnosed with diabetes mellitus. The majority of MAFLD diagnoses were based on body mass index (70.6%) and diabetes mellitus history (23.5%), biomarkers that are easily obtained. At 6, 12, 24, and 36 months after LT, MAFLD patients had higher levels of fasting blood glucose (6 months: <em>p</em> = 0.004, 12 months: <em>p</em> = 0.038) and higher trend of body mass index value and plasma triglyceride level but no significance.</p></div><div><h3>Conclusions</h3><p>MAFLD was more easily diagnosed in LT recipients with abnormal liver function and higher in prevalence than NAFLD. A larger sample size research is required to validate these conclusions.</p></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"1 3","pages":"Pages 194-198"},"PeriodicalIF":0.0,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947822000627/pdfft?md5=3b103e8a8998a85e4d1804ade8f6dec7&pid=1-s2.0-S2772947822000627-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82803065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}